Vol. 2 No. 5 (2022): May
Reimbursement Recommendations

Prasterone (Intrarosa)

Published May 3, 2022

Key Messages

  • CADTH recommends that Intrarosa should be reimbursed by public drug plans for the treatment of postmenopausal vulvovaginal atrophy (VVA) if certain conditions are met.
  • Intrarosa should only be covered for patients who are eligible for vaginal estrogen products that are currently reimbursed by public drug plans for the treatment of postmenopausal VVA.
  • Intrarosa should only be reimbursed if treatment with Intrarosa does not cost more than treatment with the least costly vaginal estrogen product currently reimbursed for the treatment of postmenopausal VVA.